Prothena Corporation plc (PRTA)
NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
As of 10:06AM EDT. Market open.
| Previous close | 21.65 |
| Open | 21.61 |
| Bid | 21.74 x 200 |
| Ask | 22.03 x 200 |
| Day's range | 21.42 - 22.06 |
| 52-week range | 19.65 - 77.13 |
| Volume | |
| Avg. volume | 552,316 |
| Market cap | 1.177B |
| Beta (5Y monthly) | 0.30 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Prothena Reports First Quarter 2024 Financial Results and Business Highlights
DUBLIN, May 08, 2024--Prothena today reported financial results for the first quarter of 2024 and provided business highlights
- Business Wire
Prothena to Report First Quarter 2024 Financial Results on May 8
DUBLIN, Ireland, May 01, 2024--Prothena announced that it will report first quarter 2024 financial results on Wednesday, May 8, 2024, after the close of the U.S. financial markets.
- Business Wire
Prothena Announces Review on Birtamimab Mechanism of Action and Pharmacological Characteristics Published in Leukemia & Lymphoma
DUBLIN, April 15, 2024--Prothena today announced a publication related to the mechanism of action, pharmacological characteristics, and clinical utility of birtamimab.
© 2024 Yahoo. All rights reserved.